betaine anhydrous for solution
novitium pharma llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of majo
betaine anhydrous for oral solution- betaine anhydrous for solution
oakrum pharma, llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects
betaine anhydrous for oral solution- betaine powder, for solution
lukare medical, llc - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: none. risk summary available data from a limited number of published case reports and postmarketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of betaine in hum
betaine powder, for solution
cosette pharmaceuticals, inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and post marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and
betaine anhydrous powder, for solution
eton pharmaceuticals, inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine anhydrous for oral solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: • cystathionine beta-synthase (cbs) deficiency • 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency • cobalamin cofactor metabolism (cbl) defect none. 8.1 pregnancy risk summary available data from a limited number of published case reports and post-marketing experience with betaine anhydrous for oral solution use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 lactation risk summary there are no data on the presence of betaine in human or animal milk, the effects on the breastfed child, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betaine anhydrous for oral solution and any potential adverse effects on the breastfed child from betaine anhydrous for oral solution or from the underlying maternal condition. 8.4 pediatric use the safety and effectiveness of betaine anhydrous for oral solution have been established in pediatric patients. the majority of case studies of homocystinuria patients treated with betaine anhydrous for oral solution have been pediatric patients, including patients ranging in age from 24 days to 17 years [see clinical studies (14)]. children younger than 3 years of age may benefit from dose titration [ see dosage and administration (2.1) ].
cystadane- betaine powder, for solution
recordati rare diseases - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 1 g in 1 g - cystadane ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and postmarketing experience with cystadane use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnanc
cystadane- betaine powder, for solution
rare disease therapeutics, inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 6 g - cystadane® (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. pregnancy category c: animal reproduction studies have not been conducted with cystadane. it is also not known whether cystadane can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. cystadane should be given to a pregnant woman only if clearly needed. it is not known whether cystadane is excreted in human milk. use only if clearly needed. the majority of case studies of homocystinuria patients treated with cystadane have been pediatric patients, including patients ranging in age from 24 days to 17 years [see clinical studies (14)]. children younger than 3 years of age may benefit
cystadane- betaine powder, for solution
ropack inc. - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 1 g in 1 g - cystadane ® (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. pregnancy category c: animal reproduction studies have not been conducted with cystadane. it is also not known whether cystadane can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. cystadane should be given to a pregnant woman only if clearly needed. it is not known whether cystadane is excreted in human milk. use only if clearly needed. the majority of case studies of homocystinuria patients treated with cystadane have been pediatric patients, including patients ranging in age from 24 days to 17 years [see clinical studies ( 14)]. children younger than 3 years of age may benefit from dose titration [see dosag
livertel formulation: each ml contains: ascorbic acid (vitamin c) 1 mg cyanocobalamin (vitamin b12) 0.2 mcg calcium d-gluconate 1 mg zinc 0.3 mg manganese 0.025 mg copper 0.025 mg selenium 1 mcg taurine 10 mg glycine 3.5 mg l-lysine 3 mg cysteine 1 mg methionine 1 mg l-carnitine 1 mg glutamine 1 mg l-tryptophane 0.5 mg betaine 10 mcg tricholine citrate 5 mg oral solution
emcure pharma philippines inc.; distributor: emcure pharma philippines inc. - ascorbic acid (vitamin c) , cyanocobalamin (vitamin b12) minerals , amino acids , tricholine citrate (vet.) - oral solution - formulation: each ml contains: ascorbic acid (vitamin c) 1 mg cyanocobalamin (vitamin b12) 0.2 mcg calcium d-gluconate 1 mg zinc 0.3 mg manganese 0.025 mg copper 0.025 mg selenium 1 mcg taurine 10 mg glycine 3.5 mg l-lysine 3 mg cysteine 1 mg methionine 1 mg l-carnitine 1 mg glutamine 1 mg l-tryptophane 0.5 mg betaine 10 mcg tricholine citrate 5 mg
betaine hcl tab 500mg tablet
gahler enterprises ltd. - betaine hydrochloride - tablet - 500mg - betaine hydrochloride 500mg - digestants